Conjugate Vaccine Market Share

Global Conjugate Vaccine Market Overview

It is estimated, The conjugate vaccines market will register  USD 14.8 billion at a CAGR of 9.9% during the forecast period 2023-2032. Conjugate depicts joined, and the conjugate vaccine is when the vaccine joins a specific germ with a strong part, typically a carrier protein or antigen, which elicits a strong immune response targeted to key parts of the virus or bacteria. The advantage of the Conjugate Vaccine is increasing the market value. The improved immune system, long-lasting protection, protects the infants from infections, created with herd immunity are some of the key advantages of the market that is improving the market.

Conjugate vaccines are made by covalently bonding a weak antigen to the strong antigen. This vaccine is given to boost the immunity of the individual. Some examples are the Haemophilus influenzae type B (Hib) vaccine and pneumococcal vaccine. Increased revenue for the vaccines is driving the market. Most bacteria have polysaccharide coating in their body, which helps them escape the immune system; the vaccines are linked with special polylactide coating to an organism by producing response and immunity.

during the forecast period. According to the Conjugate Vaccine Market Forecast, the increasing immunization for the people and awareness for the safety from different diseases are creating ample growth.

The growing number of regulatory approvals for conjugate vaccines and their rising use in adult populations are factors that are projected to propel the market. It is anticipated that the increasing acceptance of the meningococcal conjugate vaccination would drive the expansion of the conjugate vaccine market. The growth of the market for pneumococcal and meningococcal vaccines may be attributed to the expansion of the industry's leading players.

 The market is strengthening due to the growing availability of conjugate vaccinations for adults. The spread of information about the benefits of vaccinations is a key factor in their success. Market expansion for combination vaccines is also expected to benefit from an increase in the prevalence of infectious diseases. Consumers' growing awareness of the need of illness prevention is also expected to support the market for conjugate vaccines.

The number of businesses investing in vaccine development is growing. The market is expanding as a result of new entries and rising investment from existing firms. A large window of opportunity has opened up in the conjugate vaccine market as the need for immunizations rises. The future of the market is forecasted, along with a comprehensive analysis of the current state of the market.

August 2023: In order to combat typhoid in Madagascar's Arivonimamo and Antananarivo-Atsimondrano regions, the International Vaccine Institute (IVI) in South Korea and the Madagascar Institute for Vaccine Research (MIVR) at the University of Antanararivo started a massive immunization program that same year, in August 2023. The goal of this campaign is to assess the efficacy of Vi-CRM197, a typhoid conjugate vaccine (TCV) pre-qualified by the World Health Organization, in a high-burden setting prior to incorporating it into routine vaccination programmes in Madagascar as part of the Typhoid Conjugate Vaccine Introduction in Madagascar (TyMA) project.

Covid-19 analysis 

During the impact of the novel coronavirus, most sectors faced loss and disappointment except the healthcare sector. The Healthcare sector was all alone and tried to treat all the patients and improve the situation globally. There were times when there was less medical equipment; during that time, the sector faced issues, but several new entrants made the market stable. The vaccine market was all in the sky after the betterment of the situation. People wanted to take preventive measures for every disease beforehand for the safety of themselves and their families. COVID 19 impacted the Conjugate Vaccine Market, and the market gained growth.

Conjugate Vaccine Market Trends

• Key drivers

The increasing use of conjugate vaccines for adults and the improving number of regulatory approvals for conjugate vaccines is expected to drive the market. Increasing approval for the meningococcal conjugate vaccine is estimated to propel the growth of the conjugate vaccine market. Increasing key players for developing and introducing vaccines for pneumococcal and meningococcal vaccines will accelerate the market. The increasing number of conjugate vaccines for adults is improving the market. Rising awareness regarding the vaccination programs will promote growth. 

• Market challenges

More technology development to carry out new research is a challenge for the Market. The vaccine's ineffectiveness and low strength of the vaccine is a challenge for the market. The market will have to overcome the challenge to increase Conjugate Vaccine Market Size.

• Market opportunities

Many companies are increasing in the research and development of vaccines. New entrants and increasing investment by the players are opening up new opportunities for the market. Growing demand for vaccination is forming ample opportunity for the Conjugate Vaccine Market Growth. Market Outlook shows the growing situation and the detailed representation of the market.

• Market restraints

Although the number is rising and the awareness is improving, making people acquire the vaccine, the low strength of the vaccine is a restraining factor for the market. The vaccine effects are also not up to the market because infants and adults are still getting infected by the disease after the preventive conjugate vaccine. A long period of interval between introducing new conjugate vaccines in fewer economic countries will hinder the market for further acceleration.

Conjugate Vaccine Market Segment Insights

The Conjugate Vaccine Market is segmented into type, indication and end-user. All of the mentioned segments will improve the market position and make the market hold the largest market share in the forecast period.

Conjugate Vaccine Type Insights

The market is divided into HaemophilusB, Monovalent, Multivalent, Others based on the segment type. The multivalent segment dominates the Conjugate Vaccine Market and is expected to experience high growth in the forecast period. The multivalent experience more growth as it contains two or more strains or serotypes of the same antigen, and it protects several strains of pneumococcal bacteria infection. Other factors due to the growth are cost-effectiveness. The rise of vaccine manufacturers is adding more growth to the market due to improvement in government initiatives and technological advancement due to the market's expansion shortly. Other types of markets are contributing to market growth.

Conjugate Vaccine Indication Insights

The Conjugate Vaccine Market is classified into Influenza Pneumococcal, Meningococcal and Others. The pneumococcal segment will hold the largest CAGR in the forecast period. It is expected that other segments will also follow the same growth and continue adding value to the market.

Conjugate Vaccine End-Users Insights

Pediatrics and Adults are the variables of the end-user segment. Pediatrics will experience the largest growth as infants and children are more prone to most diseases, due to which they will require treatment sooner and will get affected by the infection. The adult segment will also accelerate the market, but the children will hold the CAGR.

July 2023, the World Health Organization (WHO) prequalified MenFive, the first conjugate vaccination that protects against the five most common forms of meningococcal meningitis in Africa. MenFive is a vaccine that protects against meningococcal serogroups A, C, W, Y, and X. It was developed by the Serum Institute of India Pvt Ltd (SII) and the Pan American Health Organization (PATH) over the course of 13 years with critical funding from the UK government's Foreign, Commonwealth and Development Office. In addition, it is the only vaccination available to protect against meningitis caused by meningococcal group X, a disease that is becoming more linked to meningitis epidemics in Africa.

July 2023, positive immune responses were shown in both vaccine-naive and previously vaccinated patients in two phase 3 studies of V116, an experimental 21-valent pneumococcal conjugate vaccine developed by Merck and scheduled for release in July 2023. Positive immune responses to serotypes specific to V116 were also reported among vaccine-naive individuals in STRIDE-3, in addition to statistically significant responses to serotypes shared with PCV20. These findings lend credence to the idea that V116, by increasing coverage to include 8 serotypes not presently covered in any approved vaccine, might represent an essential new preventative option for adults, independent of past pneumococcal vaccination history.

Conjugate Vaccine Regional Insights

The Conjugate Vaccine Market is studied in Europe, America, Asia, the pacific, the middle east and Africa. America holds the highest growth of the market as the region is using the most rate of vaccine to prevent the disease and favorable condition by the region's government. Europe is in the second position of the Conjugate Vaccine Market as in the region the funds for the research and development activities are increasing for the preventive measures. The Asia Pacific is showcasing a significant growth rate, and the region will contribute to the growth rate in the forecast period due to the rising prevalence of infectious diseases. In the region, research is going on to take prevention for the diseases caused to children. The increasing population and the prevalence of diseases in India and China are expected to increase the Conjugate Vaccine Market Value.

Competitive Intensity Within The Industry   

Competitive analysis of the market shows the companies contributing to developing the market. The players are adopting new strategies to increase the marketplace over the world. The companies collaborate with other players and manufacturers to develop new projects and for the new launchers to multiply the consumer and the Conjugate Vaccine MarketShare. Prominent key players who are operating in the Conjugate Vaccine Market globally are

• GlaxoSmithKline plc.


• Merck & Co., Inc. U.S


• Fab life.in India


• SutroVax Inc. U.S


• Sanofi Pasteur SA. France


• Pfizer U.S


• Sinovac Biotech Ltd.China


• IDT Biologics GmbH


• GreenSignal Bio Pharma Limited in India


• Taj Pharmaceuticals Limited in India


• Bavarian Nordic U.S

Recent development  

• According to a study, routine use of a typhoid conjugate vaccine with a catch-up campaign through age 15 could prevent approx. Over ten years, sixty-seven million cases and 826,000 deaths were caused by typhoid fever.


• World health organization prequalified the first typhoid conjugate vaccine in 2018, and it will be accessible in areas where it is extremely needed.

Report Overview 

The report of the Conjugate Vaccine Market includes a selective and substantial amount of information like market dynamics scenarios and opportunities during the forecast period. The Conjugate Vaccine Market Trends are also valued in the market, and based on the trends, the market is showcasing the development. Subsegmnets of the market depict qualitative information, which pushes the market forward. The market's competitive landscape includes more entrants and the strategies made by the consistent players. It also shows the market situation in the past years; the future situation is also expected in the report. The recent development of the market is shown in the report to light on the present scenario of the market.

Conjugate Vaccine Market Segmentation

Conjugate Vaccine Type Outlook

• Haemophilus B


• Monovalent


• Multivalent


• Others

Conjugate Vaccine Indication Outlook

• Influenza Pneumococcal


• Meningococcal


• Others

Conjugate Vaccine end-users Outlook

• Pediatrics 


• Adults